Breakfast vs. fasting: new study tests how a meal changes drug levels
NCT ID NCT06415045
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial in 18 healthy adults tested whether eating a high-fat, high-calorie meal changes how the body absorbs a single 18 mg dose of Nerandomilast (BI 1015550). Participants took the drug either after fasting overnight or right after a heavy meal, and researchers measured drug levels in the blood. The goal is to understand if food affects the drug's concentration, which will guide future dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nerandomilast (BI 1015550, JASCAYD®)
What this could lead to
If successful, this study will show whether Nerandomilast should be taken with or without food, helping guide future dosing instructions.
What could go wrong
This is a very early, small study in healthy people, not patients. Results may not predict effects in the intended disease population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany